74 clinical trials found.

Amyloidosis

• A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation
• An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment

Brain Tumor

• A PHASE II CLINICAL TRIAL EVALUATING DCVax-BRAIN, AUTOLOGOUS DENDRITIC CELLS PULSED WITH TUMOR LYSATE ANTIGEN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME
• A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
• ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
• ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/ PNET Patients
• ACNS0822: A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas
• N0574: Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases

Breast Cancer

• CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of Her2-Positive Primary Breast Cancer
• CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
• E3108: A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
• Inflammatory Breast Cancer Initiative: Creation of an Inflammatory Breast Cancer Research Database
• NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
• NSABP-B43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
• Randomized, Open-Label Study of Abiraterone Acetate (JNJ 212082) plus Prednisone with or without Exemestane in Postmenopausal Women with ER+ Metastatic Breast Cancer Progressing after Letrozole or Anastrozole Therapy

Chemotherapy-Induced Nausea

• ACCL1032: A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Cisplatin

Colon Cancer

• CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Colorectal Cancer

• Phase 1/2 study of PX-866 and Cetuximab
• Randomized Clinical Trial Evaluating the Impact Of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers

Dermatology: Psoriasis

• A Multicenter, Open Registry of Patients with Psoriasis Who are Candidates for Systemic Therapy Including Biologics

Endometrial Cancer

• A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma GOG-0249
• A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed By Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma GOG-0258

Fibromyalgia

• Tai Chi and Aerobic Exercise for Fibromyalgia

Glaucoma/Ophthalmology

• A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension

Head and Neck Cancer

• Phase 1/2 study of PX-866 and Cetuximab
• RTOG 0920 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Heme Malignacies: Myelodysplastic Syndrome

• BMT CTN 0901: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Heme Malignancies: Graft Versus Host Disease

• Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Heme Malignancies: Leukemia

• A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects with Philadelphia Chromosome Positive Leukemias
• AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)
• AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
• AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
• AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
• AALL1131, Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
• ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
• BMT CTN 0901: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
• E1906: A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
• E2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age =60 Years)

Heme Malignancies: Lymphoblastic Lymphoma

• AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

HIV: CVD

• The impact of omega 3 fatty acids on vascular function in HIV (HOST study)

Immune Function

• Immunological impact of high olive oil consumption

Liver Cancer

• A Multicenter, Randomized, Double-blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) versus Placebo and BSC as Second-line Treatment in Patients With Hepatocellular Carcinoma Following First-line Therapy With Sorafenib
• E1208: A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion

Lung Cancer

• ACOSOG Z4099/RTOG 1021: A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
• E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

Lyme Disease

• Xenodiagnosis of Lyme Disease

Multiple Myeloma

• A Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Three Days a Week for Three Weeks Followed by a 9 Day Rest Period in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
• A Phase II Clinical Trial for Untreated Patients with Multiple Myeloma Eligible for Stem Cell Transplant: Lenalidomide (Revlimid®) plus Low-dose Dexamethasone (Ld x 4 cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance
• A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients with Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
• C70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

Neuro-Oncology

• A PHASE II CLINICAL TRIAL EVALUATING DCVax-BRAIN, AUTOLOGOUS DENDRITIC CELLS PULSED WITH TUMOR LYSATE ANTIGEN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME
• A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
• ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
• ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/ PNET Patients
• ACNS0822: A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas
• N0574: Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases

Neuroblastoma

• ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

Ovarian, Primary Peritoneal, Fallopian Tube Cancer

• A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles Of Single Agent Paclitaxel or CT-2103 (IND#70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy GOG-0212

Pancreatic Cancer

• A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy

Phase I: Advanced Solid Tumors

• A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination with Sorafenib in Adult Patients with Advanced Solid Tumors
• Phase 1 Study of the Anti-VEGFR-3 Monoclonal antibody IMC-3C5 in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

Polycystic Kidney Disease

• A Multi-center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
• A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects with Autosomal Dominant Polycystic Kidney Disease

Prostate Cancer

• C70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

Pulmonary Arterial Hypertension

• AMBITION: A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension
• Ambrisentan: The use of An ERA (Ambrisentan) in patients with Porto-pulmonary hypertension. A Multicenter Open Label Trial
• Compass 2: Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic ptients with pulmonary arterial hypertension - A multicenter, double-blind, randomized, placebo-controlled, parallel group, prospective, event driven Phase IV study
• PATENT-1 Study: A randomized, double-blind, placebo-controlled, multi-centre and multi-national study to assess the efficacy and safety of different doses of a new drug (BAY 63 2521), given to patients with symptomatic Pulmonary Arterial Hypertension

Rhabdomyosarcoma (RMS)

• ARST0921: A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma

Rheumatology: Arthritis

• Tai Chi and Physical Therapy for Knee Osteoarthritis

Veno-Occlusive Disease (VOD)

• Defibrotide For Patients With Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)

Wilms Tumor

• AREN0532: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
• AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
• Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors